Annabel Biruete1, Tzu-Wen L Cross2, Jacob M Allen3, Brandon M Kistler4, Henriette de Loor5, Pieter Evenepoel6, George C Fahey7, Laura Bauer7, Kelly S Swanson8, Kenneth R Wilund9. 1. Division of Nutritional Sciences, University of Illinois, Urbana, Illinois; Division of Nephrology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 2. Division of Nutritional Sciences, University of Illinois, Urbana, Illinois; Department of Nutrition Science, Purdue University, West Lafayette, Indiana. 3. Department of Kinesiology and Community Health, University of Illinois, Urbana, Illinois. 4. Department of Nutrition and Health Science, Ball State University, Muncie, Indiana. 5. KU Leuven Department of Microbiology and Immunology, Laboratory of Nephrology, Leuven, Belgium. 6. KU Leuven Department of Microbiology and Immunology, Laboratory of Nephrology, Leuven, Belgium; Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium. 7. Department of Animal Sciences, University of Illinois, Urbana, Illinois. 8. Division of Nutritional Sciences, University of Illinois, Urbana, Illinois; Department of Animal Sciences, University of Illinois, Urbana, Illinois. 9. Division of Nutritional Sciences, University of Illinois, Urbana, Illinois; Department of Kinesiology and Community Health, University of Illinois, Urbana, Illinois. Electronic address: kwilund@illinois.edu.
Abstract
OBJECTIVE: The prebiotic fiber inulin has been studied in individuals undergoing hemodialysis (HD) due to its ability to reduce gut microbiota-derived uremic toxins. However, studies examining the effects of inulin on the gut microbiota and derived metabolites are limited in these patients. We aimed to assess the impact of a 4-week supplementation of inulin on the gut microbiota composition and microbial metabolites of patients on HD. DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled, crossover study, twelve HD patients (55 ± 10 y, 50% male, 58% Black American, BMI 31.6 ± 8.9 kg/m2, 33% diabetes mellitus) were randomized to consume inulin [10 g/d for females; 15 g/d for males] or maltodextrin [6 g/d for females; 9 g/d for males] for 4 weeks, with a 4-week washout period. We assessed the fecal microbiota composition, fecal metabolites (short-chain fatty acids (SCFA), phenols, and indoles), and plasma indoxyl sulfate and p-cresyl sulfate. RESULTS: At baseline, factors that explained the gut microbiota variability included BMI category and type of phosphate binder prescribed. Inulin increased the relative abundance of the phylum Verrucomicrobia and its genus Akkermansia (P interaction = 0.045). Inulin and maltodextrin resulted in an increased relative abundance of the phylum Bacteroidetes and its genus Bacteroides (P time = 0.04 and 0.03, respectively). Both treatments increased the fecal acetate and propionate (P time = 0.032 and 0.027, respectively), and there was a trend toward increased fecal butyrate (P time = 0.06). Inulin did not reduce fecal p-cresol or indoles, or plasma concentrations of p-cresyl sulfate or indoxyl sulfate. CONCLUSIONS: A 4-week supplementation of inulin did not lead to major shifts in the fecal microbiota and gut microbiota-derived metabolites. This may be due to high variability among participants and an unexpected increase in fecal excretion of SCFA with maltodextrin. Larger studies are needed to determine the effects of prebiotic fibers on the gut microbiota and clinical outcomes to justify their use in patients on HD.
OBJECTIVE: The prebiotic fiber inulin has been studied in individuals undergoing hemodialysis (HD) due to its ability to reduce gut microbiota-derived uremic toxins. However, studies examining the effects of inulin on the gut microbiota and derived metabolites are limited in these patients. We aimed to assess the impact of a 4-week supplementation of inulin on the gut microbiota composition and microbial metabolites of patients on HD. DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled, crossover study, twelve HD patients (55 ± 10 y, 50% male, 58% Black American, BMI 31.6 ± 8.9 kg/m2, 33% diabetes mellitus) were randomized to consume inulin [10 g/d for females; 15 g/d for males] or maltodextrin [6 g/d for females; 9 g/d for males] for 4 weeks, with a 4-week washout period. We assessed the fecal microbiota composition, fecal metabolites (short-chain fatty acids (SCFA), phenols, and indoles), and plasma indoxyl sulfate and p-cresyl sulfate. RESULTS: At baseline, factors that explained the gut microbiota variability included BMI category and type of phosphate binder prescribed. Inulin increased the relative abundance of the phylum Verrucomicrobia and its genus Akkermansia (P interaction = 0.045). Inulin and maltodextrin resulted in an increased relative abundance of the phylum Bacteroidetes and its genus Bacteroides (P time = 0.04 and 0.03, respectively). Both treatments increased the fecal acetate and propionate (P time = 0.032 and 0.027, respectively), and there was a trend toward increased fecal butyrate (P time = 0.06). Inulin did not reduce fecal p-cresol or indoles, or plasma concentrations of p-cresyl sulfate or indoxyl sulfate. CONCLUSIONS: A 4-week supplementation of inulin did not lead to major shifts in the fecal microbiota and gut microbiota-derived metabolites. This may be due to high variability among participants and an unexpected increase in fecal excretion of SCFA with maltodextrin. Larger studies are needed to determine the effects of prebiotic fibers on the gut microbiota and clinical outcomes to justify their use in patients on HD.
Authors: Annabel Biruete; Kathleen M Hill Gallant; Stephen R Lindemann; Gretchen N Wiese; Neal X Chen; Sharon M Moe Journal: J Ren Nutr Date: 2019-03-04 Impact factor: 3.655
Authors: W H Wilson Tang; Zeneng Wang; David J Kennedy; Yuping Wu; Jennifer A Buffa; Brendan Agatisa-Boyle; Xinmin S Li; Bruce S Levison; Stanley L Hazen Journal: Circ Res Date: 2014-11-05 Impact factor: 17.367
Authors: Steven R Gill; Mihai Pop; Robert T Deboy; Paul B Eckburg; Peter J Turnbaugh; Buck S Samuel; Jeffrey I Gordon; David A Relman; Claire M Fraser-Liggett; Karen E Nelson Journal: Science Date: 2006-06-02 Impact factor: 47.728
Authors: Hannah D Holscher; Jamie L Doligale; Laura L Bauer; Vishnupriya Gourineni; Christine L Pelkman; George C Fahey; Kelly S Swanson Journal: Food Funct Date: 2014-03-25 Impact factor: 5.396
Authors: M Rossi; D W Johnson; H Xu; J J Carrero; E Pascoe; C French; K L Campbell Journal: Nutr Metab Cardiovasc Dis Date: 2015-04-09 Impact factor: 4.222
Authors: Wing Sun Faith Chung; Alan W Walker; Petra Louis; Julian Parkhill; Joan Vermeiren; Douwina Bosscher; Sylvia H Duncan; Harry J Flint Journal: BMC Biol Date: 2016-01-11 Impact factor: 7.431
Authors: María Antonia Martínez-Sánchez; María Ángeles Núñez-Sánchez; Andrés Balaguer-Román; Alba Oliva-Bolarín; Gabriel Pujante-Gilabert; Quiteria Hernández-Agüera; María José Mesa-López; Juan Egea-Valenzuela; María Isabel Queipo-Ortuño; Antonio José Ruiz-Alcaraz; Mercedes Ferrer-Gómez; José Gil-Martínez; Bruno Ramos-Molina Journal: J Clin Med Date: 2022-06-22 Impact factor: 4.964
Authors: Guobin Su; Xindong Qin; Changyuan Yang; Alice Sabatino; Jaimon T Kelly; Carla Maria Avesani; Juan Jesus Carrero Journal: Clin Kidney J Date: 2021-09-14